How to Get Repatha (Evolocumab) in North Carolina

What Is Repatha and Why Cardiologists in North Carolina Use It

Repatha is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab preserves LDL receptor recycling and drives LDL-C dramatically lower. The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The FOURIER trial enrolled 27,564 patients with established ASCVD already on optimized statin therapy and randomized them to evolocumab or placebo. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% (from a median baseline of 92 mg/dL to 30 mg/dL) and cut the primary composite endpoint of CV death, MI, stroke, coronary revascularization, or unstable angina by 15% (hazard ratio 0.85 to 95% CI 0.79, 0.92, P<0.001). [2] The key secondary endpoint of CV death, MI, or stroke fell by 20% (HR 0.80 to 95% CI 0.73, 0.88, P<0.001). [2]

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol designates PCSK9 inhibitors as appropriate add-on therapy when LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe in very-high-risk ASCVD patients, or when LDL-C remains at or above 100 mg/dL in HeFH patients. [3] North Carolina cardiologists, lipidologists, and primary care physicians routinely reference this guideline when writing Repatha prescriptions.

Approximately 1 in 250 people carries a heterozygous familial hypercholesterolemia mutation, according to data compiled by the CDC. [4] With North Carolina's population of roughly 10.7 million, an estimated 42,800 residents may have HeFH, many of them undiagnosed or undertreated on statin monotherapy alone.

Who Can Prescribe Repatha in North Carolina

Any licensed prescriber with authority to write Schedule-legend prescriptions in North Carolina can prescribe evolocumab. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) operating within their scope of practice.

North Carolina grants full practice authority to certified nurse practitioners under NCGS § 90-18.2, meaning NPs do not require a physician collaboration agreement to prescribe. [5] PAs in North Carolina operate under a supervising physician relationship but have broad prescribing rights for non-controlled legend drugs like evolocumab. Telehealth providers holding a valid North Carolina medical or advanced-practice license may prescribe Repatha to North Carolina patients after conducting a clinically appropriate synchronous or asynchronous evaluation, consistent with the North Carolina Medical Board's telehealth policy. [6]

Cardiologists and lipid specialists at academic centers such as UNC Health, Duke Heart Center, Wake Forest Baptist Health, and Atrium Health all routinely initiate Repatha. However, a referral to a specialist is not required. A primary care physician or a telehealth prescriber can initiate the prescription provided the clinical criteria are met.

What Labs You Need Before Starting Repatha in North Carolina

A fasting lipid panel is the core pre-prescription requirement. Clinicians need a documented LDL-C value to satisfy payer prior authorization criteria and to confirm a clinically appropriate indication. The ACC/AHA guideline recommends obtaining a fasting lipid panel 4 to 12 weeks after initiating any lipid-lowering therapy to confirm response. [3]

Standard pre-Repatha labs in North Carolina clinical practice include:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin)
• HbA1c if the patient has risk factors for diabetes
• TSH if hypothyroidism has not been excluded as a cause of secondary hyperlipidemia
• Lipoprotein(a) if the treating provider suspects Lp(a)-driven residual risk [7]

Most North Carolina commercial payers require at least two separate fasting lipid panels documenting LDL-C at or above the threshold (typically 70 mg/dL or 100 mg/dL depending on risk tier) before approving prior authorization. Telehealth-based prescribers can often coordinate lab orders through Quest Diagnostics or LabCorp locations throughout North Carolina, with results returned electronically. Lab results dated within the prior 90 days are generally accepted by payers.

Liver function tests do not require a specific threshold for Repatha initiation; however, clinicians document them to rule out active hepatic disease and to establish a baseline. No routine creatine kinase monitoring is mandated for PCSK9 inhibitors, distinguishing them from statins in patients with myopathy concerns. [1]

How to Get a Repatha Prescription in North Carolina Step by Step

Getting a Repatha prescription in North Carolina follows a predictable sequence regardless of whether you see a provider in person or via telehealth.

Step 1. Find a prescriber. Schedule an appointment with a cardiologist, primary care physician, or a telehealth service licensed in North Carolina. Multiple telehealth platforms now provide synchronous video visits and can prescribe evolocumab to NC residents without requiring an office visit.

Step 2. Complete labs. Order a fasting lipid panel and CMP. Results should document LDL-C above the guideline threshold after maximally tolerated statin therapy, or a confirmed familial hypercholesterolemia diagnosis. If you have a recent lipid panel from a different provider, transfer those records.

Step 3. Confirm statin optimization. Payers expect documentation that the patient is on the highest tolerated statin dose or has a documented intolerance. A prior authorization request without this documentation will typically be denied on first review.

Step 4. Obtain the prescription. The prescriber sends a Repatha prescription electronically to a specialty or retail pharmacy. Many NC providers use Walgreens Specialty Pharmacy, CVS Specialty, or Accredo. Some mail-order specialty pharmacies licensed to operate in North Carolina ship the auto-injector or prefilled SureClick syringe with cold-pack delivery.

Step 5. Prior authorization. The pharmacy or the prescriber's office submits prior authorization documentation to the patient's payer. Commercial payers in North Carolina, including Blue Cross NC, Aetna, Cigna, and UnitedHealthcare, all maintain PCSK9 inhibitor PA criteria aligned broadly with ACC/AHA guidelines. [3] The PA process typically takes 3 to 14 business days.

Step 6. Apply for cost support. Amgen's Repatha co-pay program offers eligible commercially insured patients a co-pay as low as $0 per month. Patients who are uninsured or whose insurance does not cover Repatha may apply for the Amgen Safety Net Foundation program.

Step 7. Receive the medication. Specialty pharmacies ship Repatha refrigerated. Once delivered, store at 36°F to 46°F (2°C to 8°C). The SureClick autoinjector may be kept at room temperature for up to 30 days.

Telehealth Prescribing for Repatha in North Carolina

North Carolina permits telehealth prescribing of non-controlled prescription drugs, including evolocumab, when a valid patient-prescriber relationship exists. The North Carolina Medical Board has stated that a telehealth visit can establish a patient-provider relationship sufficient for prescribing when the provider obtains a thorough medical history, reviews available records, and conducts an appropriate clinical evaluation. [6]

This means a North Carolina resident with documented hyperlipidemia can complete a video visit with a board-certified physician or NP, upload recent lab results, and receive an evolocumab prescription without ever leaving home. HealthRX connects North Carolina patients with licensed prescribers who review lipid panels, confirm ASCVD risk, and submit prior authorization documentation on the patient's behalf.

Typical telehealth visit duration for a Repatha consultation is 20 to 30 minutes. The provider reviews cardiovascular history, current medications, prior statin trials, and lab values. If labs are outdated, the provider orders new labs through a local draw site before finalizing the prescription.

From the initial telehealth consultation to first injection, the typical timeline in North Carolina runs 10 to 21 days when prior authorization is submitted promptly and the patient's lab work is current. Urgent cases with documented acute cardiovascular events may qualify for expedited PA review (72 hours or fewer under NC state insurance regulations).

North Carolina Medicaid and Insurance Coverage for Repatha

North Carolina Medicaid (NC Medicaid Managed Care) does not cover Repatha for primary hyperlipidemia, familial hypercholesterolemia, or established ASCVD as a stand-alone indication. NC Medicaid's preferred drug list restricts PCSK9 inhibitor coverage to patients with a Type 2 diabetes comorbidity meeting specific LDL-C thresholds, a narrower coverage policy than most commercial payers. [8]

For commercially insured North Carolina patients, coverage is widely available but nearly always subject to prior authorization. Blue Cross and Blue Shield of North Carolina covers evolocumab for ASCVD and HeFH with documented LDL-C of 70 mg/dL or above after maximally tolerated statin plus ezetimibe. State Health Plan members (covering NC state employees) follow a similar tier requiring step therapy documentation. Aetna, Cigna, and UnitedHealthcare plans sold in North Carolina align their criteria with the ACC/AHA 2022 guideline. [3]

Medicare Part D plans available in North Carolina generally cover Repatha on specialty tier (Tier 4 or Tier 5). Patient cost-sharing under Part D can be substantial; however, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D takes effect in 2025 and will benefit many Medicare-enrolled NC patients on Repatha. [9]

Patients denied on first PA submission have the right to request an internal appeal within 60 days of denial under North Carolina insurance law. A physician letter of medical necessity citing FOURIER outcomes data and the ACC/AHA guideline language increases the probability of appeal success. [2, 3]

Prior Authorization Documentation Requirements in North Carolina

Prior authorization for Repatha in North Carolina requires a specific package of clinical documentation. Missing even one element is the leading reason for initial denial.

The standard documentation set includes:

• Most recent fasting LDL-C value with lab date (typically within 90 days)
• Documentation of current statin and dose, or documented statin intolerance with clinical notes
• Documentation of ezetimibe trial or documented intolerance (required by most NC commercial payers)
• Confirmed diagnosis code: E78.01 (HeFH), E78.02 (HoFH), or I25.10/I25.119 (ASCVD) with supporting clinical history
• Prescriber's attestation that the patient meets ACC/AHA criteria for intensification beyond statin plus ezetimibe
• For HoFH: genetic testing or clinical diagnosis documentation

The Endocrine Society's 2017 clinical practice guideline on familial hypercholesterolemia explicitly states: "We recommend PCSK9 inhibitor therapy in patients with HeFH at very high cardiovascular risk whose LDL-C is not controlled on maximally tolerated lipid-lowering therapy." [10] Quoting guideline language directly in a prior authorization letter strengthens the clinical narrative.

A provider submitting a PA without ezetimibe documentation should proactively include a note explaining why ezetimibe was not tolerated or is contraindicated. GI intolerance, hepatotoxicity, or drug interaction concerns are accepted medical reasons. Without this note, most NC commercial payers will issue a step-therapy denial requiring ezetimibe trial before Repatha approval.

Transferring a Repatha Prescription to North Carolina

Patients relocating to North Carolina or establishing care with a new NC provider can transfer an active Repatha prescription. The practical steps differ slightly depending on whether the original prescription is at a retail pharmacy or a specialty pharmacy.

For retail pharmacies, NC Pharmacy Practice Act § 90-85.15 permits prescription transfers between licensed pharmacies. The receiving NC pharmacy contacts the original pharmacy to transfer remaining refills. Specialty pharmacy transfers require the patient's new NC prescriber to submit a new prescription with updated PA documentation, because most PA approvals are prescriber-specific and do not transfer with the Rx.

Patients moving from another state should schedule a telehealth or in-person visit with a North Carolina provider before their existing medication supply runs out. Most specialty pharmacies will ship up to a 30-day bridge supply while the new PA is processed, provided the prescriber requests a bridge and the patient has documented continuity of care. Repatha is dosed every 2 weeks or monthly, so even a single month's supply provides meaningful continuity.

Lab results from another state are accepted by NC payers as long as they are dated within 90 days. If labs are older than 90 days, the new NC prescriber will typically reorder a fasting lipid panel before submitting the PA.

503A Compounding and Evolocumab in North Carolina

North Carolina has licensed 503A compounding pharmacies, which are state-regulated facilities authorized to compound patient-specific prescriptions. However, evolocumab is an FDA-approved biological monoclonal antibody, and federal compounding law prohibits 503A pharmacies from compounding copies of commercially available biological products without a specific patient-need justification that cannot be met by the commercial product. [11]

In practice, no 503A pharmacy in North Carolina compounds evolocumab. Patients seeking evolocumab must use FDA-approved Repatha from Amgen, dispensed through a licensed specialty or retail pharmacy. There is no compounded equivalent available, and any product marketed as "compounded evolocumab" would lack FDA approval, efficacy validation, and safety data from trials like FOURIER. [2]

Patients who cannot afford brand-name Repatha should contact Amgen's patient assistance programs rather than seeking compounded alternatives. The Amgen Safety Net Foundation provides free medication to qualifying uninsured or underinsured patients; eligibility is income-based with household income thresholds up to 500% of the federal poverty level.

Repatha Dosing and Administration for North Carolina Patients

Evolocumab comes in two dosing regimens. The 140 mg subcutaneous injection is given every 2 weeks using a single-use prefilled SureClick autoinjector or prefilled syringe. The 420 mg monthly dose uses three consecutive 140 mg injections within 30 minutes or a single-use Pushtronex on-body infusor system. [1]

Injection sites include the abdomen, thigh, or upper arm. Patients rotate sites and avoid areas that are tender, bruised, or scarred. The autoinjector is designed for self-injection at home without medical supervision after initial training. Most specialty pharmacies in North Carolina include patient training materials and telephone pharmacist support with the first shipment.

Adverse reactions observed in FOURIER included injection-site reactions (2.1% vs. 1.6% placebo), nasopharyngitis, and upper respiratory tract infection, all at rates not significantly different from placebo. [2] Serious hepatic events and myopathy were not elevated above placebo rates, supporting the favorable tolerability profile that makes long-term adherence achievable.

The first LDL-C response check is typically scheduled 4 to 8 weeks after initiation. Mean LDL-C reductions of 59% were achieved in FOURIER; individual responses may vary, particularly in HoFH patients where residual receptor activity determines magnitude of response. [2] Patients with HoFH may require dose titration or combination with lomitapide or apheresis.

What to Expect for Timeline and Delivery in North Carolina

From first telehealth consult to first injection, most North Carolina patients experience a timeline of 10 to 21 days when prior authorization proceeds without appeal. Here is a realistic breakdown:

• Day 1: Telehealth or in-person consultation, labs ordered if not current
• Days 2 to 5: Lab results returned (Quest and LabCorp have 48 to 72-hour turnaround for lipid panels at most NC draw sites)
• Day 5 to 6: Prescription transmitted to specialty pharmacy, PA submitted by prescriber office
• Days 6 to 20: PA decision from commercial payer (standard review 3 to 14 business days; expedited 72 hours)
• Days 21 to 24: Specialty pharmacy ships Repatha cold-pack; UPS or FedEx overnight to NC address
• Day 22 to 25: First injection administered at home

If the PA is denied on first review, appeal timelines add 30 to 60 days. Patients facing imminent cardiovascular risk may qualify for a peer-to-peer review request, where the prescribing physician speaks directly with the payer's medical director. Peer-to-peer reviews resolve PA denials in 60% to 70% of cases when the prescriber can cite LDL-C values, trial data, and guideline criteria directly. [3]